共 50 条
- [1] Low doses of humanized anti-CD20 antibody, IMMU-106 (hA20), in refractory or recurrent NHL: Phase I/II results[J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Morschhauser, F.Leonard, J. P.Fayad, L.Coiffier, B.Petillon, M.Coleman, M.Horne, H.Teoh, N.Wegener, W. A.Goldenberg, D. M.
- [2] Phase I/II results of a second-generation humanized anti-CD20 antibody, IMMU-106 (hA20), in NHL.[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 429S - 429SMorshhauser, F.Leonard, J. P.Coiffier, B.Petillon, M.Coleman, M.Bahkti, A.Teoh, N.Wegener, W. A.Goldenberg, D. M.
- [3] Rituximab-relapsing patients with non-Hodgkins lymphoma respond even at lower doses of humanized anti-CD20 antibody, IMMU-106 (hA20):: Phase I/II results.[J]. BLOOD, 2006, 108 (11) : 769A - 769AMorschhauser, FranckLeonard, John P.Fayad, LuisCoiffier, BertrandSchuster, Stephen J.Dyer, Martin J. S.Petillon, Marie-OdileColeman, MortonBahkti, AminaHorne, HeatherXu, LiTeoh, NickWegener, William A.Goldenberg, David M.
- [4] Initial safety and efficacy results of a second-generation humanized anti-CD20 antibody, IMMU-106 (bA20), in non-Hodgkin's lymphoma.[J]. BLOOD, 2005, 106 (11) : 683A - 683AMorschhauser, FLeonard, JPCoiffier, BPetillon, MOColeman, MBahkti, ASapra, PTeoh, NWegener, WAHorak, IDGoldenberg, DM
- [5] Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma[J]. CLINICAL CANCER RESEARCH, 2004, 10 (08) : 2868 - 2878Stein, RQu, ZXChen, SRosario, AShi, VHayes, MHorak, IDHansen, HJGoldenberg, DM
- [6] Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3346 - 3353Morschhauser, FranckLeonard, John P.Fayad, LuisCoiffier, BertrandPetillon, Marie-OdileColeman, MortonSchuster, Stephen J.Dyer, Martin J. S.Horne, HeatherTeoh, NickWegener, William A.Goldenberg, David M.
- [7] Anti-lymphoma activity of a new humanized anti-CD20 monoclonal antibody, hA20[J]. FASEB JOURNAL, 2003, 17 (07): : C123 - C123Goldenberg, DMOn, ZXHorak, IDHansen, HStein, R
- [8] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma[J]. BLOOD, 2010, 116 (21) : 1148 - 1149Christian, BethAlinari, LapoEarl, Christian TylerWilding, EmilyQuinion, CarlLustberg, MarkBenson, Don M., Jr.Jones, Jeffrey A.Byrd, John C.Wegener, William A.Goldenberg, David M.Baiocchi, Robert A.Blum, Kristie A.
- [9] Interim results of a phase I/II study of ocrelizumab, a new humanised Anti-CD20 antibody in patients with relapsed/refractory follicular non-hodgkin's lymphoma[J]. BLOOD, 2007, 110 (11) : 199A - 199AMorschhauser, FranckMarlton, PaulaVitolo, UmbertoLinden, OlaSeymour, JohnCrump, MichaelCoiffier, BertrandPulsoni, AlessandroBelch, AndrewLerch, ErikaKimby, EvaArnljots, KristinaWassner, ElisabethMendila, Myriam
- [10] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma[J]. BLOOD, 2011, 118 (21) : 1584 - 1584Christian, BethAlinari, LapoJones, Jeffrey A.Benson, Don M., Jr.Flynn, Joseph M.Porcu, PierluigiLustberg, Mark E.Phelps, MitchellPoi, MingChung, DianaQuinion, CarlByrd, John C.Wegener, WilliamGoldenberg, David M.Baiocchi, Robert A.Blum, Kristie A.